<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fragile X syndrome genotype-phenotype correlations</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fragile X syndrome genotype-phenotype correlations</h1>
<div class="graphic"><div class="figure"><div class="ttl">Fragile X syndrome genotype-phenotype correlations</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2">Mutation type</td> <td class="subtitle1" rowspan="2">Number of CGG trinucleotide repeats</td> <td class="subtitle1" rowspan="2">Methylation status of <em>FMR1</em></td> <td class="subtitle1" colspan="2">Clinical status</td> </tr> <tr> <td class="subtitle2">Male</td> <td class="subtitle2">Female</td> </tr> <tr> <td>Premutation</td> <td>Approximately 55 to 200</td> <td>Unmethylated</td> <td>At risk for FXTAS*</td> <td> <p>At risk for FXPOI and FXTAS</p> Potential increased risk of other fragile X-associated disorders* </td> </tr> <tr> <td>Full mutation</td> <td>&gt;200</td> <td>Completely methylated</td> <td>100% have ID</td> <td>Approximately 50% with ID, approximately 50% normal intellect</td> </tr> <tr> <td>Repeat size mosaicism</td> <td>Varies between premutation and full mutation in different cell lines</td> <td>Partial: Unmethylated in the premutation cell line; methylated in the full mutation cell line</td> <td>Nearly 100% affected with ID; may be higher functioning<sup>¶</sup> than males with full mutation</td> <td>Highly variable: Ranges from normal intellect to affected</td> </tr> <tr> <td>Methylation mosaicism</td> <td>&gt;200</td> <td>Partial: Mixture of methylated and unmethylated cell lines</td> <td>Nearly 100% affected with ID; may be higher functioning<sup>¶</sup> than males with full mutation</td> <td>Highly variable: Ranges from normal intellect to affected</td> </tr> <tr> <td>Unmethylated full mutation</td> <td>&gt;200</td> <td>Unmethylated</td> <td>Nearly all have ID but often have high functioning ID to low-normal intellect</td> <td>Highly variable: Ranges from normal intellect to affected</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>CGG: cytosine-guanine-guanine; <em>FMR1</em>: fragile X mental ribonucleoprotein 1; FXTAS: fragile X-associated tremor/ataxia syndrome; FXPOI: fragile X-associated primary ovarian insufficiency; ID: intellectual disability; IQ: intelligence quotient; ADHD: attention deficit hyperactivity disorder.</p>
<p>* Both males and females with premutations have been reported to have slightly elevated rates of some manifestations of fragile X syndrome, such as facial features, behavioral problems, learning disabilities, ADHD, and anxiety<sup>[1-4]</sup>. Some studies also indicate an increased rate of additional outcomes, such as depression, pain disorders, autoimmune disorders, and other health outcomes<sup>[5,6]</sup>.</p>
¶ <em>FMR1</em> pathogenic variants are complex alterations involving nonclassic gene-disrupting variants (trinucleotide repeat expansion) and abnormal gene methylation. This complexity at the gene level affects production of the FMR1 protein and may result in an atypical presentation in which affected individuals occasionally have an IQ above 70, the traditional demarcation denoting ID.</div><div class="graphic_reference">Reference:
<ol>
<li>Riddle JE, Cheema A, Sobesky WE, et al. Phenotypic involvement in females with the FMR1 gene mutation. Am J Ment Retard. 1998; 102:590.</li>
<li>Bourgeois JA, Coffey SM, Rivera SM, et al. A review of fragile X premutation disorders: expanding the psychiatric perspective. J Clin Psychiatry 2009; 70:852.</li>
<li>Hunter JE, Abramowitz A, Rusin M, Sherman SL. Is there evidence for neuropsychological and neurobehavioral phenotypes among adults without FXTAS who carry FMR1 premutation? A review of current literature. Genet Med 2009; 11:79.</li>
<li>Chonchaiya W, Nguyen DV, Au J, et al. Clinical involvement in daughters of men with fragile X-associated tremor ataxia syndrome. Clin Genet 2010; 78:38.</li>
<li>Wheeler A, Raspa M, Hagerman R, et al. Implications of the FMR1 premutation for children, adolescents, adults, and their families. Pediatrics 2017; 139:S172.</li>
<li>Hagerman RJ, Protic D, Rajaratnam A, et al. Fragile X-associated neuropsychiatric disorders (FXAND). Front Psychiatry 2018; 9:564.</li>
</ol>
<p class="extra_spacing_top">Reproduced with permission from: Hunter JE, Berry-Kravis E, Hipp H, Todd PK. FMR1 Disorders (November 2019). In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright © 1993-2023, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved. Available at: <a href="https://www.ncbi.nlm.nih.gov/books/NBK1384/" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK1384/</a> (Accessed on October 4, 2022).</p></div><div id="graphicVersion">Graphic 73067 Version 17.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
